#Distribütör
LightNews LightNews
mhodgkissauthor.bsky.social
Hi
I had my novella with publishers since August ERD April (6/9 months a normal turnaround time)
I’m trying to get into main stream shops bookstore.uk etc say need uk based distributor

what is normal turn around time from submission to publishing?
how do I over come my publishers in USA I’m uk
February 19, 2026 at 12:57 PM
epsteinweb.bsky.social
EFTA01396851.jpg
#epsteinweb #efta01396851
https://epsteinweb.org
EFTA01396782 | EFTA01396851 GLDUS126 Pacific Life Insurance Co SOF IV — Project Klein Exclusive deal Fund Secondary Expected Closing Date: Key investment data Invested Capital at close Discount to NAV at close Gross multiple at close % funded at close Use of leverage Description — Motivated quality GP aiming to recapitalize and extend their 2007 midmarket pan-European fund while providing liquidity to LPs — Key value driver is largest independent UK premium distributor in its segment, well positioned to benefit from market tailwinds — Second largest asset is a network of medical and cosmetics UK clinics with a private and affluent customer base — The portfolio also includes an Italian digital marketing company and a management consulting company with blue chip customers — Glendower Capital retains discretion on use of follow-on capital June 2018 1 €60-100m (US$80-120m) >5% 1.1x 80% No GP-led Secondary Seller type: Transaction summary Number of companies Strategy Region Industries Average age at purchase Single Asset Deal Alternative funds 4 Mid-market buyout Europe / UK Business services / Healthcare services 9 years Investment rationale / Glendower Team angle Glendower Team angle — Ability to quickly deliver a bespoke solution leveraging Glendower's track record in complex transactions — Ability to perform extensive diligence, including onsite visits, full access to companies' management and industry specialists — Long 15-year relationship with the GP founder EFTA01396851
February 19, 2026 at 12:51 PM
epsteinweb.bsky.social
EFTA01396777.jpg
#epsteinweb #efta01396777
https://epsteinweb.org
EFTA01396742 | EFTA01396777 distributor. The Paying Agent in Switzerland is Banque Cantonale de Geneve, 17 Quai de l'Ile, CH-1207 Geneva, Switzerland (the "Paying Agent"). Interests may be subscribed and/or redeemed with the Paying Agent. A handling commission will be charged by the Paying Agent. If a subscription or redemption is made through the Paying Agent, instructions and money must be received by the paying agent at least 24 hours before the appropriate dealing cut-off time. Glendower Capital SOF IV, L.P. 8 EFTA01396777
February 19, 2026 at 12:47 PM
epsteinweb.bsky.social
Parts 1-2/2 — EFTA01396633.jpg
#epsteinweb #efta01396633
https://epsteinweb.org
EFTA01396322 | EFTA01396633 disputes arising out of the duties of the Representative. Any dispute related to the distribution of Interests in and from Switzerland shall be subject to the jurisdiction of the registered office of the distributor. The Paying Agent in Switzerland is Banque Cantonale de Geneve, 17 Quai de l'Ile, CH-1207 Geneva, Switzerland (the "Paying Agent"). Interests may be subscribed and/or redeemed with the Paying Agent. A handling commission will be charged by the Paying Agent. If a subscription or redemption is made through the Paying Agent, instructions and money must be received by the paying agent at least 24 hours before the appropriate dealing cut-off time. The fees and expenses associated with the representation, paying agency and other distribution items may be charged to the Fund. As applicable, the actual amount of such fees and expenses will be disclosed in the audited financial statements. In distributing the Interests in Switzerland, the General Partner is authorized to pass on distribution fees to the distributors and sales partners listed below: • distributors subject to authorization as defined in Article 19 al. 1 of the CISA (Swiss or foreign distributors regulated in their home jurisdiction); • distributors that are not required to obtain an authorization as defined under Article 19 al 1 of the CISA and article 8 of CISO (financial intermediaries regulated by FINMA, banks, insurance companies, fund managers, representatives; • Sales partners who place Interests in the Fund with their customers exclusively through a written commissionbased investment management or advisory mandate (e.g., independent asset managers or advisors). When a retrocession payment may give rise to a conflict of interest, the recipient of the retrocession must ensure transparent disclosure and inform investors, unsolicited and free of charge, of the amount of retrocession it may receive for distribution. Upon request, the recipient must disclose the actual amount of retrocession received for distributing the Confidential Private Placement Memorandum 96 EFTA01396633
February 19, 2026 at 12:40 PM
epsteinweb.bsky.social
EFTA01396174.jpg
#epsteinweb #efta01396174
https://epsteinweb.org
EFTA01396105 | EFTA01396174 GLDUS125 Gerald Ford SOF IV — Project Klein Exclusive deal Fund Secondary Expected Closing Date: Key investment data Invested Capital at close Discount to NAV at close Gross multiple at close % funded at close Use of leverage Description — Motivated quality GP aiming to recapitalize and extend their 2007 midmarket pan-European fund while providing liquidity to LPs — Key value driver is largest independent UK premium distributor in its segment, well positioned to benefit from market tailwinds — Second largest asset is a network of medical and cosmetics UK clinics with a private and affluent customer base — The portfolio also includes an Italian digital marketing company and a management consulting company with blue chip customers — Glendower Capital retains discretion on use of follow-on capital June 2018 1 €60-100m (US$80-120m) >5% 1.1x 80% No GP-led Secondary Seller type: Transaction summary Number of companies Strategy Region Industries Average age at purchase Single Asset Deal Alternative funds 4 Mid-market buyout Europe / UK Business services / Healthcare services 9 years Investment rationale / Glendower Team angle Glendower Team angle — Ability to quickly deliver a bespoke solution leveraging Glendower's track record in complex transactions — Ability to perform extensive diligence, including onsite visits, full access to companies' management and industry specialists — Long 15-year relationship with the GP founder EFTA01396174
February 19, 2026 at 12:17 PM
epsteinweb.bsky.social
Parts 1-2/2 — EFTA01396069.jpg
#epsteinweb #efta01396069
https://epsteinweb.org
EFTA01395758 | EFTA01396069 disputes arising out of the duties of the Representative. Any dispute related to the distribution of Interests in and from Switzerland shall be subject to the jurisdiction of the registered office of the distributor. The Paying Agent in Switzerland is Banque Cantonale de Geneve, 17 Quai de l'Ile, CH-1207 Geneva, Switzerland (the "Paying Agent"). Interests may be subscribed and/or redeemed with the Paying Agent. A handling commission will be charged by the Paying Agent. If a subscription or redemption is made through the Paying Agent, instructions and money must be received by the paying agent at least 24 hours before the appropriate dealing cut-off time. The fees and expenses associated with the representation, paying agency and other distribution items may be charged to the Fund. As applicable, the actual amount of such fees and expenses will be disclosed in the audited financial statements. In distributing the Interests in Switzerland, the General Partner is authorized to pass on distribution fees to the distributors and sales partners listed below: • distributors subject to authorization as defined in Article 19 al. 1 of the CISA (Swiss or foreign distributors regulated in their home jurisdiction); • distributors that are not required to obtain an authorization as defined under Article 19 al 1 of the CISA and article 8 of CISO (financial intermediaries regulated by FINMA, banks, insurance companies, fund managers, representatives; • Sales partners who place Interests in the Fund with their customers exclusively through a written commissionbased investment management or advisory mandate (e.g., independent asset managers or advisors). When a retrocession payment may give rise to a conflict of interest, the recipient of the retrocession must ensure transparent disclosure and inform investors, unsolicited and free of charge, of the amount of retrocession it may receive for distribution. Upon request, the recipient must disclose the actual amount of retrocession received for distributing the Confidential Private Placement Memorandum 96 EFTA01396069
February 19, 2026 at 12:12 PM
epsteinweb.bsky.social
EFTA01395750.jpg
#epsteinweb #efta01395750
https://epsteinweb.org
EFTA01395715 | EFTA01395750 distributor. The Paying Agent in Switzerland is Banque Cantonale de Geneve, 17 Quai de l'Ile, CH-1207 Geneva, Switzerland (the "Paying Agent"). Interests may be subscribed and/or redeemed with the Paying Agent. A handling commission will be charged by the Paying Agent. If a subscription or redemption is made through the Paying Agent, instructions and money must be received by the paying agent at least 24 hours before the appropriate dealing cut-off time. Glendower Capital SOF IV, L.P. 8 EFTA01395750
February 19, 2026 at 11:53 AM
epsteinweb.bsky.social
Parts 1-2/2 — EFTA01395605.jpg
#epsteinweb #efta01395605
https://epsteinweb.org
EFTA01395294 | EFTA01395605 disputes arising out of the duties of the Representative. Any dispute related to the distribution of Interests in and from Switzerland shall be subject to the jurisdiction of the registered office of the distributor. The Paying Agent in Switzerland is Banque Cantonale de Geneve, 17 Quai de l'Ile, CH-1207 Geneva, Switzerland (the "Paying Agent"). Interests may be subscribed and/or redeemed with the Paying Agent. A handling commission will be charged by the Paying Agent. If a subscription or redemption is made through the Paying Agent, instructions and money must be received by the paying agent at least 24 hours before the appropriate dealing cut-off time. The fees and expenses associated with the representation, paying agency and other distribution items may be charged to the Fund. As applicable, the actual amount of such fees and expenses will be disclosed in the audited financial statements. In distributing the Interests in Switzerland, the General Partner is authorized to pass on distribution fees to the distributors and sales partners listed below: • distributors subject to authorization as defined in Article 19 al. 1 of the CISA (Swiss or foreign distributors regulated in their home jurisdiction); • distributors that are not required to obtain an authorization as defined under Article 19 al 1 of the CISA and article 8 of CISO (financial intermediaries regulated by FINMA, banks, insurance companies, fund managers, representatives; • Sales partners who place Interests in the Fund with their customers exclusively through a written commissionbased investment management or advisory mandate (e.g., independent asset managers or advisors). When a retrocession payment may give rise to a conflict of interest, the recipient of the retrocession must ensure transparent disclosure and inform investors, unsolicited and free of charge, of the amount of retrocession it may receive for distribution. Upon request, the recipient must disclose the actual amount of retrocession received for distributing the Confidential Private Placement Memorandum 96 EFTA01395605
February 19, 2026 at 11:44 AM
trumpactiontracker.bsky.social
The Equal Employment Opportunity Commission (EEOC) sued a bottler and distributor of Coca-Cola products it accuses of sex discrimination over an employee networking event that excluded men. The lawsuit against the Coca-Cola bottler is the first by the EEOC to claim ...

TAT: [Weakening Civil Rights]
US civil rights agency sues Coca-Cola bottler over event that excluded men
Lawsuit is first by Equal Employment Opportunity Commission over workplace DEI in Trump’s second term
www.theguardian.com
February 19, 2026 at 11:32 AM
epsteinweb.bsky.social
EFTA01395085.jpg
#epsteinweb #efta01395085
https://epsteinweb.org
EFTA01395050 | EFTA01395085 distributor. The Paying Agent in Switzerland is Banque Cantonale de Geneve, 17 Quai de l'Ile, CH-1207 Geneva, Switzerland (the "Paying Agent"). Interests may be subscribed and/or redeemed with the Paying Agent. A handling commission will be charged by the Paying Agent. If a subscription or redemption is made through the Paying Agent, instructions and money must be received by the paying agent at least 24 hours before the appropriate dealing cut-off time. Glendower Capital SOF IV, L.P. 8 EFTA01395085
February 19, 2026 at 11:18 AM
epsteinweb.bsky.social
Parts 1-2/2 — EFTA01394777.jpg
#epsteinweb #efta01394777
https://epsteinweb.org
EFTA01394777 | EFTA01394777 GIOUS140 Lawrence Hirsch SOF IV — Project Klein Exclusive deal Expected Glosing Date: El Fund Secondary June 2018 StreGP-led Secondary Seller type: Key investment data ❑ Single Anet Deal Alternative funds Transaction summary Number of companies 4 Invested Capital at dose E60-100m (US$80-120m) Discount to NAV at close >5% Strategy Mid-market buyout Gross multiple at close 1.1x Region Europe / UK 0/0 funded at close 80% Industries Use of leverage No Business services / Healthcare services Average age at purchase 9 years Description Investment rationale / Glendower Team angle - Motivated quality GP aiming to recapitalize and extend their 2007 midmarket pan-European fund while providing liquidity to LPs Glendower Team angle - Ability to quickly deliver a bespoke solution leveraging Glendower's track record in complex transactions - Key value driver is largest independent UK premium distributor in its segment, well positioned to benefit from market tailwinds - Second largest asset is a network of medical and cosmetics UK clinics with a private and affluent customer base - The portfolio also includes an Italian digital marketing company and a management consulting company with blue chip customers - Glendower Capital retains discretion on use of follow-on capital - Ability to perform extensive diligence, including onsite visits, full access to companies' management and industry specialists - Long 15-year relationship with the GP founder Investment rationale - Four well-invested companies positioned to capture growth opportunities arising from ongoing changes in industry landscape - Key value driver led by industry veteran with a solid track record - Value-add potential from recently implemented cost efficiency initiatives - Opportunity to invest in identified follow-ons at closing, and to contribute additional capita! to exploit market dislocations —':or disc-km.5km perposebrgy. The irra:eti-ned ~ed above I. s.rme m'rei there is no se-latsida-e Mal investinent wgi cemmliÅe or rorm part og si Lagra invested Fortie:4m that blbe, airaibibge pr. arte furthren due diligence, prove statabe for :3OF This. slide hauld be [end and meie-wc-d in conjunetion with the important Information and "Important Perfcgmance Inforrnabon' and • Notes to Investment Pedormance sectione. Glendower Capital CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e) CONFIDENTIAL STRICTLY CONFIDENTIAL 41 DB-SDNY-0100819 SDNY_GM_00247003 EFTA01394777
February 19, 2026 at 11:02 AM
epsteinweb.bsky.social
Parts 1-2/2 — EFTA01394382.jpg
#epsteinweb #efta01394382
https://epsteinweb.org
EFTA01394382 | EFTA01394382 GLDUS129 DF Enterprises SOF IV — Project Klein Exclusive deal ❑ Expected Closing Date: Fund Secondary June 2018 NeGP-led Secondary Seller type: Key investment data ❑ Single Asset Deal Alternative funds Transaction summary Number of companies 4 Invested Capital at close E60-100m (US$80-120m) Discount to NAV at close >5% Strategy Mid-market buyout Gross multiple at close 1.1x Region Europe / UK 0/0 funded at close 80% Industries Use of leverage No Business services / Healthcare services Average age at purchase 9 years Description Investment rationale / Glendower Team angle - Motivated quality GP aiming to recapitalize and extend their 2007 midmarket pan-European fund while providing liquidity to LPs Glendower Team angle - Ability to quickly deliver a bespoke solution leveraging Glendower's track record in complex transactions - Key value driver is largest independent UK premium distributor in its segment, well positioned to benefit from market tailwinds - Second largest asset is a network of medical and cosmetics UK clinics with a private and affluent customer base - The portfolio also includes an Italian digital marketing company and a management consulting company with blue chip customers - Glendower Capital retains discretion on use of follow-on capital - Ability to perform extensive diligence, including onsite visits, full access to companies' management and industry specialists - Long 15-year relationship with the GP founder Investment rationale - Four well-invested companies positioned to capture growth opportunities arising from ongoing changes in industry landscape - Key value driver led by industry veteran with a solid track record - Value-add potential from recently implemented cost efficiency initiatives - Opportunity to invest in identified follow-ons at closing, and to contribute additional capital to exploit market dislocations reed above I. s. Foi discmskin ocaposes or y The in:a:samara pr close-d. arxi them is no guarantas that st. iiirstestineq crinplcae or roan pad o lueire IFIVApSteci p0ftl0414, 04 that it will be avaliatrie pr. aftei fultrRi due diligence. prove suitable for SOF tV This slide should be reed end ieviewed in conjunction with the 'Imponent Information and "Important Perfra mane Information and 'Notes to Investment Periormance sections Glendower Capital CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e) CONFIDENTIAL STRICTLY CONFIDENTIAL DB-SDNY-0100386 SDNY_GM_00246570 EFTA01394382
February 19, 2026 at 10:42 AM
epsteinweb.bsky.social
Parts 1-2/2 — EFTA01394011.jpg
#epsteinweb #efta01394011
https://epsteinweb.org
EFTA01394011 | EFTA01394011 GLDUS137 Forrestal Capital LLC SOF IV — Project Klein Exclusive deal Li Expected Closing Date: Fund Secondary June 2018 NeGP-led Secondary Seller type: Key investment data D Single Asset Deal Alternative funds Transaction summary Number of companies 4 Invested Capital at close E60-100m (US$80-120m) Discount to NAV at close >5% Strategy Mid-market buyout Gross multiple at close 1.1x Region Europe / UK 0/0 funded at close 80% Industries Use of leverage No Business services / Healthcare services Average age at purchase 9 years Description Investment rationale / Glendower Team angle - Motivated quality GP aiming to recapitalize and extend their 2007 midmarket pan-European fund while providing liquidity to LPs Glendower Team angle - Ability to quickly deliver a bespoke solution leveraging Glendower's track record in complex transactions - Key value driver is largest independent UK premium distributor in its segment, well positioned to benefit from market tailwinds - Second largest asset is a network of medical and cosmetics UK clinics with a private and affluent customer base - The portfolio also includes an Italian digital marketing company and a management consulting company with blue chip customers - Glendower Capital retains discretion on use of follow-on capital - Ability to perform extensive diligence, including onsite visits, full access to companies' management and industry specialists - Long 15-year relationship with the GP founder Investment rationale - Four well-invested companies positioned to capture growth opportunities arising from ongoing changes in industry landscape - Key value driver led by industry veteran with a solid track record - Value-add potential from recently implemented cost efficiency initiatives - Opportunity to invest in identified follow-ons at closing, and to contribute additional capital to exploit market dislocations For dear:akin pcaposec rjy. Tha pr reed above I.W s. flOt cliose-d. and these is no guarantee that st., 1intestine'? wit c:amok:4e or !cart o' Ivbire invested portfc4io or that it Al bei avaliab4e or. aftei fultrRi due diligence. prove suitable for :30F Di This slide should be reed end reviewed in conjunction with the 'Important Infomiation and "Important Perfra mane Information and Notes to Investment Pedormance sections Glendower Capital CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e) CONFIDENTIAL STRICTLY CONFIDENTIAL DB-SDNY-0099940 SDNY_GM_00246124 EFTA01394011
February 19, 2026 at 10:23 AM
finland.activitypub.awakari.com.ap.brid.gy
GDS appointed UK distributor for Aqua Nautica UK-based GDS Limited has been appointed as the UK distributor for Aqua Nautica water makers. In addition to UK distribution, GDS Limited will manage ne...

#Leisure #Marine #Boat #habitat #Marine […]

[Original post on marineindustrynews.co.uk]
February 19, 2026 at 11:22 AM
fareydonch501.bsky.social
When you wanna derust more in Sound Voltex but at the same time the state of Bemani in your city is held together by an online Nemesys cab still running Exceed Gear, AND with Megaindo (the Indonesian Konami distributor) ghosting the local arcades here
February 19, 2026 at 9:20 AM
epsteinweb.bsky.social
Parts 1-2/2 — EFTA01392586.jpg
#epsteinweb #efta01392586
https://epsteinweb.org
EFTA01392586 | EFTA01392586 GLOUS128 Patrick Gerschel SOF IV — Project Klein Exclusive deal Expected Glosing Date: El Fund Secondary June 2018 i Secondary Seller type: Key investment data ❑ Single Asset Deal Alternative funds Transaction summary Number of companies 4 Invested Capital at dose E60-100m (US$80-120m) Discount to NAV at close >5% Strategy Mid-market buyout Gross multiple at close 1.1x Region Europe / UK 0/0 funded at close 80% Industries Use of leverage No Business services / Healthcare services Average age at purchase 9 years Description Investment rationale / Glendower Team angle - Motivated quality GP aiming to recapitalize and extend their 2007 midmarket pan-European fund while providing liquidity to LPs Glendower Team angle - Ability to quickly deliver a bespoke solution leveraging Glendower's track record in complex transactions - Key value driver is largest independent UK premium distributor in its segment, well positioned to benefit from market tailwinds - Second largest asset is a network of medical and cosmetics UK clinics with a private and affluent customer base - The portfolio also includes an Italian digital marketing company and a management consulting company with blue chip customers - Glendower Capital retains discretion on use of follow-on capital - Ability to perform extensive diligence, including onsite visits, full access to companies' management and industry specialists - Long 15-year relationship with the GP founder Investment rationale - Four well-invested companies positioned to capture growth opportunities arising from ongoing changes in industry landscape - Key value driver led by industry veteran with a solid track record - Value-add potential from recently implemented cost efficiency initiatives - Opportunity to invest in identified follow-ons at closing, and to contribute additional capita! to exploit market dislocations —':or discustun pitrposes«i4y. The invegrnimit presereed above I. s. rimt close-i. arid there is no guarantee irivestinent w3E cieviripliÅe or !Of fl‘ pag og I re givested portfc4m Mel g avaliatge or. &tiki furttwil due diligence, prove suitabki for :3OF nr This. slide idNould be med and ieviewc-d in conjunr.ition vrlth thelmponant Informationland "Important Perfoimance Infomiabon and • Notes to Investment Pedormance sections. Glendower Capital CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e) CONFIDENTIAL STRICTLY CONFIDENTIAL DB-SDNY-0097834 SDNY_GM_00244018 EFTA01392586
February 19, 2026 at 9:10 AM
epsteinweb.bsky.social
Parts 1-2/2 — EFTA01392222.jpg
#epsteinweb #efta01392222
https://epsteinweb.org
EFTA01392222 | EFTA01392222 GLOUS144 Glenn Warren SOF IV — Project Klein Exclusive deal Li Expected Closing Date: Fund Secondary June 2018 NeGP-led Secondary Seller type: Key investment data D Single Asset Deal Alternative funds Transaction summary Number of companies 4 Invested Capital at close E60-100m (US$80-120m) Discount to NAV at close >5% Strategy Mid-market buyout Gross multiple at close 1.1x Region Europe / UK 0/0 funded at close 80% Industries Use of leverage No Business services / Healthcare services Average age at purchase 9 years Description Investment rationale / Glendower Team angle - Motivated quality GP aiming to recapitalize and extend their 2007 midmarket pan-European fund while providing liquidity to LPs Glendower Team angle - Ability to quickly deliver a bespoke solution leveraging Glendower's track record in complex transactions - Key value driver is largest independent UK premium distributor in its segment, well positioned to benefit from market tailwinds - Second largest asset is a network of medical and cosmetics UK clinics with a private and affluent customer base - The portfolio also includes an Italian digital marketing company and a management consulting company with blue chip customers - Glendower Capital retains discretion on use of follow-on capital - Ability to perform extensive diligence, including onsite visits, full access to companies' management and industry specialists - Long 15-year relationship with the GP founder Investment rationale - Four well-invested companies positioned to capture growth opportunities arising from ongoing changes in industry landscape - Key value driver led by industry veteran with a solid track record - Value-add potential from recently implemented cost efficiency initiatives - Opportunity to invest in identified follow-ons at closing, and to contribute additional capital to exploit market dislocations For discmskin pcaposes or y The in:a:go:ant ptsseraed aboveW s. flOt close-d. and these is no guarantee that st., investment w31 !Of fll pan o Ivbire IFIVApSteci p0ftl0414, 04 that n Al avaliabte or. aftei fultrRi due diligence. prove suitable for 3OF tV This slide should be reed end reviewed in conjunction with the 'Imponent Information and "Important Perfra mance Intormehon and 'Notes to Investment Performance sections Glendower Capital CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e) CONFIDENTIAL STRICTLY CONFIDENTIAL DB-SDNY-0097403 SDNY_GM_00243587 EFTA01392222
February 19, 2026 at 8:50 AM
epsteinweb.bsky.social
Parts 1-2/2 — EFTA01391879.jpg
#epsteinweb #efta01391879
https://epsteinweb.org
EFTA01391879 | EFTA01391879 GLDUS142 Ironsides Assel Mgmt SOF IV — Project Klein Exclusive deal Expected Glosing Date: El Fund Secondary June 2018 i Secondary Seller type: Key investment data ❑ Single Asset Deal Alternative funds Transaction summary Number of companies 4 Invested Capital at dose E60-100m (US$80-120m) Discount to NAV at close >5% Strategy Mid-market buyout Gross multiple at close 1.1x Region Europe / UK 0/0 funded at close 80% Industries Use of leverage No Business services / Healthcare services Average age at purchase 9 years Description Investment rationale / Glendower Team angle - Motivated quality GP aiming to recapitalize and extend their 2007 midmarket pan-European fund while providing liquidity to LPs Glendower Team angle - Ability to quickly deliver a bespoke solution leveraging Glendower's track record in complex transactions - Key value driver is largest independent UK premium distributor in its segment, well positioned to benefit from market tailwinds - Second largest asset is a network of medical and cosmetics UK clinics with a private and affluent customer base - The portfolio also includes an Italian digital marketing company and a management consulting company with blue chip customers - Glendower Capital retains discretion on use of follow-on capital - Ability to perform extensive diligence, including onsite visits, full access to companies' management and industry specialists - Long 15-year relationship with the GP founder Investment rationale - Four well-invested companies positioned to capture growth opportunities arising from ongoing changes in industry landscape - Key value driver led by industry veteran with a solid track record - Value-add potential from recently implemented cost efficiency initiatives - Opportunity to invest in identified follow-ons at closing, and to contribute additional capita! to exploit market dislocations For discw.Man psrposesr4y. The investiTrwe pr reed above I. s. close-a. ansi there is no gi-lamde-a that investineol cia.ripliÅe or !Of fl‘ pag og i :en invested portfc4io os that g Al Os. avaliatge or. snei fiattwi due diligence.. prove sugets» for 30F This. slide shauld be reed and reviewc-d in conjundion With the -Important Information and "Important Perfre manne Isnfornabon and • Notes to Investment Pedormance sections. Glendower Capital CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e) CONFIDENTIAL STRICTLY CONFIDENTIAL DB-SDNY-0096971 SDNY_GM_00243155 EFTA01391879
February 19, 2026 at 8:32 AM
kevigi.bsky.social
“How do you come up with that money, especially in a federal environment that appears to be deprioritizing investments in public transit"?

There are plans to tunnel some of the new N6 Distributor Road/ city bypass underneath a city racecourse which was outcantered by sprawl. So it could be done.
February 19, 2026 at 8:14 AM
epsteinweb.bsky.social
Parts 1-2/2 — EFTA01391255.jpg
#epsteinweb #efta01391255
https://epsteinweb.org
EFTA01391255 | EFTA01391255 GLDUS139 Third Lake Capital SOF IV — Project Klein Exclusive deal Expected Glosing Date: El Fund Secondary June 2018 StreGP-led Secondary Seller type: Key investment data ❑ Single Anet Deal Alternative funds Transaction summary Number of companies 4 Invested Capital at dose E60-100m (US$80-120m) Discount to NAV at close >5% Strategy Mid-market buyout Gross multiple at close 1.1x Region Europe / UK 0/0 funded at close 80% Industries Use of leverage No Business services / Healthcare services Average age at purchase 9 years Description Investment rationale / Glendower Team angle - Motivated quality GP aiming to recapitalize and extend their 2007 midmarket pan-European fund while providing liquidity to LPs Glendower Team angle - Ability to quickly deliver a bespoke solution leveraging Glendower's track record in complex transactions - Key value driver is largest independent UK premium distributor in its segment, well positioned to benefit from market tailwinds - Second largest asset is a network of medical and cosmetics UK clinics with a private and affluent customer base - The portfolio also includes an Italian digital marketing company and a management consulting company with blue chip customers - Glendower Capital retains discretion on use of follow-on capital - Ability to perform extensive diligence, including onsite visits, full access to companies' management and industry specialists - Long 15-year relationship with the GP founder Investment rationale - Four well-invested companies positioned to capture growth opportunities arising from ongoing changes in industry landscape - Key value driver led by industry veteran with a solid track record - Value-add potential from recently implemented cost efficiency initiatives - Opportunity to invest in identified follow-ons at closing, and to contribute additional capita! to exploit market dislocations Fot disckm.M.:in perposear4y. The irra:gi-reint ~Med above I. s. tml and theam is no scuamntam that irmestinerfi ce.i.ripliÅecte !Of fl‘ pat si Ivnira mytested pottfcau that g skiti avaliatde su. aftec feetemi due diligence., prove suitable for SOF This. slide hauld be redd and tevle-wc-d in conjunetion with the -Imponcent Information and "Important Perfoimance Inforrnabon and • Notes to Investment Pencirmance sections. Glendower Capital CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e) CONFIDENTIAL STRICTLY CONFIDENTIAL 41 DB-SDNY-0096076 SDNY_GM_00242260 EFTA01391255
February 19, 2026 at 7:59 AM
epsteinweb.bsky.social
Parts 1-2/2 — EFTA01390959.jpg
#epsteinweb #efta01390959
https://epsteinweb.org
EFTA01390959 | EFTA01390959 GLOUS113 Ch11 Mig SOF IV — Project Klein Exclusive deal Expected Glosing Date: El Fund Secondary June 2018 i Secondary Seller type: Key investment data ❑ Single Asset Deal Alternative funds Transaction summary Number of companies 4 Invested Capital at dose E60-100m (US$80-120m) Discount to NAV at close >5% Strategy Mid-market buyout Gross multiple at close 1.1x Region Europe / UK 0/0 funded at close 80% Industries Use of leverage No Business services / Healthcare services Average age at purchase 9 years Description Investment rationale / Glendower Team angle - Motivated quality GP aiming to recapitalize and extend their 2007 midmarket pan-European fund while providing liquidity to LPs Glendower Team angle - Ability to quickly deliver a bespoke solution leveraging Glendower's track record in complex transactions - Key value driver is largest independent UK premium distributor in its segment, well positioned to benefit from market tailwinds - Second largest asset is a network of medical and cosmetics UK clinics with a private and affluent customer base - The portfolio also includes an Italian digital marketing company and a management consulting company with blue chip customers - Glendower Capital retains discretion on use of follow-on capital - Ability to perform extensive diligence, including onsite visits, full access to companies' management and industry specialists - Long 15-year relationship with the GP founder Investment rationale - Four well-invested companies positioned to capture growth opportunities arising from ongoing changes in industry landscape - Key value driver led by industry veteran with a solid track record - Value-add potential from recently implemented cost efficiency initiatives - Opportunity to invest in identified follow-ons at closing, and to contribute additional capita! to exploit market dislocations yr disckm.sSon perposesr4y. The investment pjeserged above . s. rml clostei. indthare is no scuatantee that inyestineol cm-ipleaeo; forre part ot i Leire irivsted ponfcCio that be avaliatge sv. aftec fulteei due diligence. prove sugets» for SOF This. Blide hauld be releet and [evle-wc-d in conjunLtion with the -Important Information and "Important Performance Information' and • Notes to Investment Performance sections. Glendower Capital CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e) CONFIDENTIAL STR1CTLY CONFIDENTIAL DB-SDNY-0095644 SDNY_GM_00241828 EFTA01390959
February 19, 2026 at 7:43 AM
epsteinweb.bsky.social
Parts 1-3/3 — EFTA01390319.jpg
#epsteinweb #efta01390319
https://epsteinweb.org
EFTA01390319 | EFTA01390319 Important Information for Recipients in Certain Jurisdictions (5/6) For persons in Qatar. The interests in the Fund are only being offered to a limited number of investors who are willing and able to conduct an independent investiaation of the risks rivoirea ni an investment in such interests The promotional documentation does not constitute en otter to the public and is for the use on of the named addressee and should not be g: en or shown to any other parson (other than employees, agents or consultants in connection with the addressee's consideration thereof). The Fund has not been and will not be registered with the Qatar Central Bank or under any laws of the Slate of Qatar. No transaction will be concluded in your jurisdiction and any inquiries regarding the interests in the Eund should be made to ahnitower For persona in Saudi Arabia. This Presentation may may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Otters of Securities Regulations issued by the Capital Market Authority (the "CMA-). The CMA does riot make any representation as to the accuracy or completeness of Ihis Document. and expressly disclaims any liability whatsoever for any loss arising from. or incurred in reliance upon, any part of this Presentation. Prospective purchasers of the interests offered Hereby should conduct their own due diligence on the accuracy of the information relating to the interests. IF you do not understand the contents of this Presentation you should consult an authorized thancial adviser. For persons in Singapore. This Presentation is not a prospectus as defined in the Securities and Futures Act Chapter 280 of Singapore F'SFA') and has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, statutory liability under the SEA in relation to the content of prospectuses would not apply, and this Presentation should not be construed in any way as a solicitation or an offer to buy or sell any interest or investment referred to in this Presentation . You should consider carefully vaiether the investment is suitable for you. The product named m ths Presentation is not authorized or recognized by the Monetary Authority of Singapore (the "MAST) and none of its interests shares units shall be allowed to be offered to retail pubfic in Singapore. This Presentation may be distributed only ffito persons who are Institutional investors- under section 304 of the SEA For persons in South Korea. This Presentation is being provided to you for general discussion purposes only to gauge the level of interest in the relevant products. The delivery of tiles Presentation to you should not be construed in any way as soliciting investment or offering to sell any interests described in this Presentation. Rather, before the sales of any fund product. the fund will first be registered with the Financial Serves Commission in Korea and a locally licensed entity will be engaged. For persons in Switzerland. Credit Suisse provides no guarantee with regard to the content and completeness of the information and does not accept any lability for lones that might arise from making use of the information. If nothing is indicated to the contrary. all tones are unaudited The Information provided herein is fur the exclusive use of the recipient. Private equity is private equity capital investment in companies that are not traded publicly (i.e.. are not listed on a stock exchange) Private equity investments are generally illiquid and are seen as a long-term invesimenl Private equity investments, includino the investrrent oppolunity described herein. may inckide the following additional risks. fit loss of all or a substantial poftn of the inveshr's investment, (ii} investment itranariers may have Incentives to make investments that are riskier or more speculabve due to performance-based compensation. (III) lack of liquidity as there may be no secondary market. (iv) volatility of returns, iv) restrictions on transfer. (vii potential lack of drverstficaton, (vii) high fees and expenses, (vat) little or no requirement to provide periodic pricing and (ix) complex tax structures and delays rn distributina iin itsrit tax inlorrnalion to investors The representative of the Fund in. Switzerland is Hugo Fund Services SA. 6 Cours de Rive. CH-1204 Geneva (the *Representative"). The offering documents, articles of association and audited financial statements can be obtained free of cuarge from the Representative The pace of performance for interests of the Fund offered or distributed in or from Switzerland is the registered office of the Representative. The courts of the isivKon of Geneva shall have jurisdiction in relation to any disputes arising out of the duties of the Representative. Any dispute related to the distribution of interests of the Fund in and from Swilzedand shall be subject to the jurisdiction of the registered office of the distributor. The Paying Agent in StviCerland is Banque Cantonale de Geneve, 17 Quai de rile. CH-1207 Geneva. Switzerland (the Paying Agent'l. Interests may be subscribed andror redeemed with the Paying Agent. A handling commission wil€ be charged by the Paying Agent It a subscrOtion or redemption is made through the Pa grog Agent. instructions and money nvist be received by the paying agent at least 24 hours before the appropnate dealing cut-off time. Glendower Capital CONFIDENTIAL - PURSUANT TO FED. R. CRI M. P. 6(e) CONFIDENTIAL S'I'R Om), CONFIDENTIAL DB-SDNY-0094788 SDNY_GM_00240972 EFTA01390319
February 19, 2026 at 7:10 AM
epsteinweb.bsky.social
Parts 1-2/2 — EFTA01390302.jpg
#epsteinweb #efta01390302
https://epsteinweb.org
EFTA01390302 | EFTA01390302 GIDUS138 lan Slome SOF IV — Project Klein Exclusive deal Expected Glosing Date: El Fund Secondary June 2018 StreGP-led Secondary Seller type: Key investment data ❑ Single Anet Deal Alternative funds Transaction summary Number of companies 4 Invested Capital at dose E60-100m (US$80-120m) Discount to NAV at close >5% Strategy Mid-market buyout Gross multiple at close 1.1x Region Europe / UK 0/0 funded at close 80% Industries Use of leverage No Business services / Healthcare services Average age at purchase 9 years Description Investment rationale / Glendower Team angle - Motivated quality GP aiming to recapitalize and extend their 2007 midmarket pan-European fund while providing liquidity to LPs Glendower Team angle - Ability to quickly deliver a bespoke solution leveraging Glendower's track record in complex transactions - Key value driver is largest independent UK premium distributor in its segment, well positioned to benefit from market tailwinds - Second largest asset is a network of medical and cosmetics UK clinics with a private and affluent customer base - The portfolio also includes an Italian digital marketing company and a management consulting company with blue chip customers - Glendower Capital retains discretion on use of follow-on capital - Ability to perform extensive diligence, including onsite visits, full access to companies' management and industry specialists - Long 15-year relationship with the GP founder Investment rationale - Four well-invested companies positioned to capture growth opportunities arising from ongoing changes in industry landscape - Key value driver led by industry veteran with a solid track record - Value-add potential from recently implemented cost efficiency initiatives - Opportunity to invest in identified follow-ons at closing, and to contribute additional capita! to exploit market dislocations yt disckm.sSon p-teposer, r=y. The investment ~Sed above I. s. tml close-i. and thare is no øuarantee that st., 1irstestinent cmtpliÅe or !Of fl‘ pag og si Itgure invested Fortie:4m ot that g *di be, avaliabte or. aftec furtnee due diligence., prove sugets» for :3OF nr This. slide hauld be 'sted and tevle-wc-d in conjunetion vrtth the -Imponant Information and "Important Perfoimance Intorrnabon and • Notes to Investment Pedcvmance sections. Glendower Capital CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e) CONFIDENTIAL STRICTLY CONFIDENTIAL 41 DB-SDNY-0094764 SDNY_GM_00240948 EFTA01390302
February 19, 2026 at 7:09 AM
epsteinweb.bsky.social
Parts 1-4/4 — EFTA01389986.jpg
#epsteinweb #efta01389986
https://epsteinweb.org
EFTA01389986 | EFTA01389986 GLDUS132 EverWatch Financial Important Information for Recipients in Certain Jurisdictions (3/6) For persons in Hong Kong. The information memorandum in relation to any interest and/or investment referred to in this Presentation has not been approved by the Securities alio i'utures Commission of Hong Kong. Accordingly (a) any interests or secuntres may not be offered or sold and have net been offered or sold in Hong Kong. by means et any document, other Mao to 'professional investors' as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made tinder that Ordinance, or (ii) in other circumstances which do not result in the document being a -prospectus" as defined in the Companies Ordinance (Cap 622) of Hong Kong or which do not constitute an offer to the public varhin the meaning of that Ordinance, and it') no person has issued or had In its possession for the purposes of issue. and will not issue or have in its possession for the purposes of issue, whether in Hong Kong or etewtiere. any advertisement. invitation or document relating to any interest or securities, which ks directed at. or the contents of which are or are likely to be accessed or read by. the public in Hong Kong (except if permitted to do so under securities laws of Hong Kong) other than with respect to any interests or securities which are or are intended to be disposed of only to persons outside Hong Kong or only to 'professional investors" within the definition of the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance. For persons in Israel. This Presentation has not been approved by the Israel Securities Authonty arid will only be distributed to Israeli residents in a manner that will not constitute 'an offer to the public' under sections 15 and 15a of the Israel Securities Law. 572B-1968 ("the Securities Law-tor section 25 of the Joint Investment Trusts Law. 5756-1994 ;-the joint Investment Trusts Law"). as applicable. The products described in this Presentation (the 'Products') are being offered to a limited number of investors (35 investors or fewer during any given 12 month period) and/or those categories of investors listed in the First Addendum (*the Addendum') to the Securities Law, (-Sophisticated Investors") namely joint investment funds or mutual trust funds. provident kinds, insurance companies, banking corperations (purchasing Prothicts For themselves or for clients who are Sophisticated Investors). portfolio managers (purchasing Products far themselves or for clients who are Sophisticated Investors), investment advisors or investment marketers (purchasing Products for themselves). members of the Tel-Aviv Stock Exchange (purchasing Products for themselves or for clients who are Sophisticated Investors), underwriters (purchaseig Products for themselves). venture capital tends engaging mainly in the capita€ market, an entity wthich is wholly owned by Sophisticated Investors, corporations. (other than fanned for the specific purpose of an acquisition pursuant to an offer). with a shareholders equity in excess of NIS 50 million. and individuals in respect of whom the tem)s of item 0 in the Schedule to the Investment Advice Law hold true investing for their own account. in respect of which at least one of the following applies: the total value of their cash, deposits, financial assets (as defined in the Investment Advt.'s. Law) and securities traded on a stock exchange licensed under the Securities Law (together, "Liquid .Assets') exceeds NIS 8 million (approximately £1.3 million), their level of income over each of the preceding two years exceeds MS 1.2 million (approximately £200,000). or the level of income of their -family unit exceeds NIS 1 8 million (approximately £330,Ox0); or the aggregate Value of all their LYjuid Assets exceeds NIS 5 mil on (approximately £i330,000) and their level of income over each of the preceding veto years exceeds NIS 600,000 (approximately £1)X.000). or the level of income ot their 'fondly unit' exceeds NIS 000,000 (approximately £150.000), each as defined in the said Addendum. as amended from time to time, and who in each case have provided written confirmation that they qualify as Sophisticated investors. and that they are aware of the consequences of such designation and agree thereto: in all cases under circumstances that will fall within the private placement or ether exemptions of the Joint investownt Trusts Law, the Securities Law and any applicable guidelines. pronouncements or rulings issued from time to time by the Israel Securities Authority. This Presentation may not be reproduced or used for any other purpose, nor be furnished to any other person other than those to whom copies have been sent Any &three who purchases a Product is purchasing such Product for its own benefit and account and not with the an or intention of distributor: or offering such Product to other parties (other than, in the case of an °iteme which is a Sophisticated Investor by virtue ofd being a banking <animation. portfolio manager or member of the Tel-Aviv Stock Exchange. as defined in the Addendum. where such offers* is purchasing Product for another party which is a Sophisecated Investor). Nothing in this Presentation (Mould be consWered investment advice or investment marketing as defined in the Regulation of investment Counselling, Investment Marketing and Portfolio Management Law. 5755-1905. Investors are encouraged to seek competent investment counselling from a locally licensed investment counsel prior to making the investment. As a prerequisite to the receipt of a copy of this Presentation a recipient shall be required by the Fund to provide confirmation that it is a Sophisticated investor purchasing Products for its own account or where applicable. for other Sophisticated Investors This Presentation does not constitute an offer to sell or seliatation of an offer to buy any securities other than the interests in the Fund offered hereby, nor does it constitute an otter to sell to or solicitation of an offer to buy from any person or persons in any state or other Jurisdiction in which such offer or solicitation would be unlawful, or in which the person making such offer or solicit 'v'; not qualified to do so, or to a persen or persons to whom it is unlawful to make such offer or solicitation. Glendower Capital CONFIDENTIAL - PURSUANT TO FED. R. CRI M. P. 6(e) CONFIDENTIAL S'I'R Om), CONFIDENTIAL DB-SDNY-0094354 SDNY_GM_00240538 EFTA01389986
February 19, 2026 at 6:52 AM
epsteinweb.bsky.social
Parts 1-2/2 — EFTA01389964.jpg
#epsteinweb #efta01389964
https://epsteinweb.org
EFTA01389964 | EFTA01389964 GLDUS132 EverWatch Financial SOF IV — Project Klein Exclusive deal Expected Glosing Date: El Fund Secondary June 2018 StreGP-led Secondary Seller type: Key investment data ❑ Single Anet Deal Alternative funds Transaction summary Number of companies 4 Invested Capital at dose E60-100m (US$80-120m) Discount to NAV at close >5% Strategy Mid-market buyout Gross multiple at close 1.1x Region Europe / UK 0/0 funded at close 80% Industries Use of leverage No Business services / Healthcare services Average age at purchase 9 years Description Investment rationale / Glendower Team angle - Motivated quality GP aiming to recapitalize and extend their 2007 midmarket pan-European fund while providing liquidity to LPs Glendower Team angle - Ability to quickly deliver a bespoke solution leveraging Glendower's track record in complex transactions - Key value driver is largest independent UK premium distributor in its segment, well positioned to benefit from market tailwinds - Second largest asset is a network of medical and cosmetics UK clinics with a private and affluent customer base - The portfolio also includes an Italian digital marketing company and a management consulting company with blue chip customers - Glendower Capital retains discretion on use of follow-on capital - Ability to perform extensive diligence, including onsite visits, full access to companies' management and industry specialists - Long 15-year relationship with the GP founder Investment rationale - Four well-invested companies positioned to capture growth opportunities arising from ongoing changes in industry landscape - Key value driver led by industry veteran with a solid track record - Value-add potential from recently implemented cost efficiency initiatives - Opportunity to invest in identified follow-ons at closing, and to contribute additional capita! to exploit market dislocations yt disansain praposes«4y. The irr.reetrerirg preserged above I. s. close-i. and the is no øuaranters tbal tre, investineol cearipliÅe or !Of fl‘ pat og a Iveire givested portfc4io tbet g *fli airaliatge or. after !urteri due diligence. prove &uteble for :3OF nr This. Blide hauld be leer' and ievicerred in conjunLtion vrlth the -Imponant Information and "Important Perfoimance Intorrnabon and • Notes to Investment Penormance sectior*. Glendower Capital CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e) CONFIDENTIAL STRICTLY CONFIDENTIAL 41 DB-SDNY-0094332 SDNY_GM_00240516 EFTA01389964
February 19, 2026 at 6:51 AM